Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer
Breast Neoplasms
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
exemestane, aspirin, quality of life
Study Type
Study Phase
Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Name: aspirin Type: Drug
Name: Exemestane Type: Drug
Overall Status
This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 80 Years
Minimum Age: 50 Years
Gender: Female
Criteria: Inclusion Criteria:

- Breast cancer after surgery postmenopausal

Exclusion Criteria:

- contraindication of aspirin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China
Status: Recruiting
Contact: Peng Yuan, M.D. - 86-135 0127 0834 -
Start Date
July 2011
Completion Date
July 2014
Chinese Academy of Medical Sciences
Chinese Academy of Medical Sciences
Record processing date processed this data on July 28, 2015 page